ALVO
NASDAQ · Biotechnology
Alvotech Sa
$3.26
+0.13 (+4.15%)
Open$3.22
Previous Close$3.13
Day High$3.29
Day Low$3.21
52W High$11.85
52W Low$3.42
Volume—
Avg Volume594.7K
Market Cap1.18B
P/E Ratio17.01
EPS$0.21
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+873.0% upside
Current
$3.26
$3.26
Target
$31.72
$31.72
$22.31
$31.72 avg
$46.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 615.09M | 146.14M | 133.98M |
| Net Income | -289,876,443 | 28.46M | 26.13M |
| Profit Margin | -47.1% | 19.5% | 19.5% |
| EBITDA | 11.59M | 50.85M | 43.53M |
| Free Cash Flow | — | 28.40M | 33.36M |
| Rev Growth | +131.4% | +3.3% | +20.0% |
| Debt/Equity | — | 0.48 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |